News

The discovery of the second pre-clinical candidate under the collaboration that the companies entered into in 2008 has triggered €1m milestone payment to Ablynx. Ablynx chairman and CEO

The contract funded by NIH is valued up to €60m ($75m) and covers a ten year period. Evotec chief operating officer Dr Mario Polywka said the NIH long

The collaboration will leverage synchrotron X-ray crystallography to design the pharmaceuticals based on the three-dimensional structure of proteins. The research will primarily focus on infectious diseases caused by

On receiving CE Mark, Quidel now plans to launch the product in Europe. The product has already carved a place in some parts of the world market, including

The study will measure the difference of ketoprofen amount found in the bloodstream, when topically applied under different conditions along with the study of the dose percentage when

JHP president and CEO Stuart Hinchen said customers look at JHP’s established infrastructure to progress products from clinical to commercial supply. ”Additionally, our cGMP compliance record and experienced

Omeros’ proprietary DTLacO technology is an ex vivo antibody discovery platform that pairs an engineered chicken B-cell line with antibody selection strategies and also has antibody repertoire from

The study revealed that the Nanobody’s specific structure, stability and small size made possible the convenient route of administration where antibodies have been unsuccessful. The double-blind, randomized trial

Both vaccines are designed to induce humoral and cellular immune responses that target the circumsporozoite protein antigen of Plasmodium falciparum. Under the grant, Protein Potential will use its